NASDAQ:SLXN Silexion Therapeutics Q3 2025 Earnings Report $0.40 -0.06 (-13.70%) As of 12:24 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Silexion Therapeutics EPS ResultsActual EPS-$28.80Consensus EPS -$34.00Beat/MissBeat by +$5.20One Year Ago EPSN/ASilexion Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASilexion Therapeutics Announcement DetailsQuarterQ3 2025Date11/12/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Silexion Therapeutics Earnings HeadlinesSilexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update3 hours ago | globenewswire.comSilexion Therapeutics Prices $2.5 Million Securities Offering; Shares Down Pre-BellAugust 12 at 9:33 AM | finance.yahoo.comThe world’s least risky AI stock?Whitney Tilson, senior editor at Stansberry Research, has identified a company he calls the world's safest AI stock, one most investors have never heard of. The firm sits at the intersection of AI, energy, and defense, and one of America's most famous investors reportedly put roughly half his fund into it. In recent years it has returned more than Apple, Amazon, and the S&P 500 combined. Tilson has released a free presentation naming the company and its ticker symbol, no payment or email required.August 14 at 1:00 AM | Stansberry Research (Ad)Silexion Therapeutics Prices $2.5 Million Public Offering of Ordinary Shares and WarrantsAugust 11 at 8:30 PM | quiverquant.comQSilexion Therapeutics Announces Pricing of $2.5 Million Public OfferingAugust 11 at 8:01 PM | globenewswire.comImmunotherapy's Biggest Blind Spot Is a $7 Billion Market. Silexion May Have a Way In (NASDAQ: SLXN)August 10, 2026 | markets.businessinsider.comSee More Silexion Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Silexion Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Silexion Therapeutics and other key companies, straight to your email. Email Address About Silexion TherapeuticsSilexion Therapeutics (NASDAQ:SLXN) LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.View Silexion Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Cerebras Sells Off After Earnings: Is This a Market Disconnection?Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?Sandisk’s Margins Look Like Software. Can They Last?SpaceX’s First Earnings Report Only Made Wall Street More DividedCAVA Earnings: The Easiest Comp of the Year Meets a Tough ValuationFranco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not Demand Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
